HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Sanex Buy, Colgate Boosts Its Personal-Care Game In Europe

This article was originally published in The Rose Sheet

Executive Summary

By acquiring Unilever's Sanex brand for roughly $940 million, New York-based Colgate-Palmolive is strengthening its presence in Europe and rounding out its global product portfolio with a premium-priced, "therapeutic" personal-care line, the firm says.

You may also be interested in...



Colgate Doubles Down On Premium Skin Care With $1.7bn Filorga Acquisition

Back in April, CEO Noel Wallace noted Colgate’s interest in further skin-care M&A during his first quarterly presentation at the firm’s helm. The Filorga purchase is significantly bigger than 2018 deals that whet Colgate’s appetite for high-growth, high-margin skin care and represents a gateway to the fast-growing travel retail channel.

Colgate Spreads Sanex Skin Care Around Europe To Spur Growth

Colgate highlights expansion plans for its Sanex skin care brand with line extensions in hand and body lotion, aspiring to capture European market share from established players including Beiersdorf, L'Oreal and J&J.

Colgate Looks To European Sanex Expansion For Growth

Colgate-Palmolive highlighted expansion plans for its Sanex skin-care brand at the Consumer Analyst Group of New York conference Feb. 19. With line extensions in hand and body lotion, the firm aspires to capture European market share from established players including Beiersdorf, L'Oreal and J&J.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel